Keymed Biosciences Inc. (KEYMED BIO-B) aktie

Keymed Biosciences Inc., a biotechnology company, engages in the discovery and development of biological therapies in the autoimmune and oncology therapeutic areas in Mainland China, the United States, and the United Kingdom. The company develops Kangyueda for the treatment of moderate-to-severe atopic dermatitis in adults, chronic rhinosinusitis with nasal polyps, and seasonal allergic rhinitis; CMG901/AZD0901, an antibody drug conjugate for treatment of advanced solid tumors; CM512, a TSLP x IL-13 bispecific antibody in Phase I clinical study; and CM518D1, an antibody drug conjugate drug in open-label Phase I/II clinical trial. It is also developing CM336, a CMA x CD3 bispecific antibody in an open-label Phase I/II clinical study for the treatment of patients with relapsed or refractory multiple myeloma; CM313 in Phase II clinical study in subjects with primary immune thrombocytopenia; CM383, an Aß protofibrils antibody in Phase Ib clinical study; and CM559, a N3pG Aß antibody in Phase I clinical study. In addition, the company is involved in the development of CM350, a GPC3 x CD3 bispecific antibody in Phase I/II clinical study; CM326, a TSLP antibody; CM355/ICP-B02/PRO-203, a CD20 x CD3 bispecific antibody; and CM369/ICP-B05, an anti-C-C motif chemokine receptor 8 monoclonal antibody. It has an out-licence agreement with Belenos Biosciences, Inc.; Platina Medicines Ltd; Prolium Biosciences, Inc.; and Timberlyne Therapeutics, Inc. The company was formerly known as 2Health Biosciences, Inc. Keymed Biosciences Inc. was founded in 2016 and is headquartered in Chengdu, the People's Republic of China.